Diffuse Intrinsic Pontine Glioma (DIPG) is the most aggressive brain tumor found in children and currently there is no cure for this disease. Every year 400-600 school age kids are affected by DIPG. The tumor is located in the pons region of the brain that controls multiple vital functions like heart beat and respiration. Therefore, surgery is impossible. The 5-year survival rate has held steady at 0% since 1950 because DIPG tumors are resistant to current standard therapies. As conventional therapies fail to work in this tumor type, we are now testing a novel chimeric antigen receptor T (CAR-T) cell therapy to defeat DIPG. CAR-T cell therapy is based on activating the patient’s own immune system to attack and kill the tumor cells. In this therapy, patient’s T cells will be isolated and modified in such a way that they will recognize the tumor cells and kill them when they are reinfused back into the patient’s body. We are now testing our novel CAR-T cells with a newly identified antigen in the DIPG mouse model and the results are impressive. Your contributions will be allow us to continue this work and to find a cure for this killer disease, eventually making a difference in these kids lives.